News
NPCE
14.28
+0.92%
0.13
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga · 2d ago
NeuroPace Price Target Announced at $18.00/Share by Keybanc
Dow Jones · 2d ago
Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18
Benzinga · 2d ago
NeuroPace initiated with an Overweight at KeyBanc
TipRanks · 2d ago
Weekly Report: what happened at NPCE last week (0907-0911)?
Weekly Report · 6d ago
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
NASDAQ · 09/10 15:30
Weekly Report: what happened at NPCE last week (0831-0904)?
Weekly Report · 09/07 09:16
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
Barchart · 09/01 16:01
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
Barchart · 08/31 15:05
Weekly Report: what happened at NPCE last week (0824-0828)?
Weekly Report · 08/31 09:17
Neuropace Earnings Call Shows Strong Growth Amid FDA Risk
TipRanks · 08/26 00:23
Weekly Report: what happened at NPCE last week (0817-0821)?
Weekly Report · 08/24 09:17
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
NASDAQ · 08/17 17:17
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
NASDAQ · 08/17 17:06
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
NASDAQ · 08/17 16:59
NeuroPace (NPCE) Receives a Buy from Cantor Fitzgerald
TipRanks · 08/17 12:36
Weekly Report: what happened at NPCE last week (0810-0814)?
Weekly Report · 08/17 09:18
Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Summit Therapeutics (SMMT) and Staar Surgical (STAA)
TipRanks · 08/13 10:50
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
NASDAQ · 08/12 15:22
More
Webull provides a variety of real-time NPCE stock news. You can receive the latest news about Neuropace Inc through multiple platforms. This information may help you make smarter investment decisions.
About NPCE
NeuroPace, Inc. is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company's RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. The Company's RNS System includes its RNS neurostimulator, its cortical strip leads and depth leads, and its Patient Remote Monitor, as well as other implantable and non-implantable accessories. The Company's product offerings also include Physician Tablet, Patient Data Management System (PDMS) and nSight Platform, which facilitate ongoing patient monitoring and streamline patient support. The PDMS is an online database.